Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis

Main Article Content

Bruce Strober
Kim A Papp
Mary Flack
Yihua Gu
Elizabeth HZ Thompson
Wendell C Valdecantos


psoriasis, risankizumab, biologic therapy


Abstract Not Available


Disclosures: Study supported by AbbVie.

Most read articles by the same author(s)

1 2 3 4 5 > >>